Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | RGS4 | P49798 | 1/20 | 0.35 |
| ▸ | RGS8 | P57771 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818736 | 0.91 | MAPT (0.32) | MAPTLMNASMN1; SMN2ACHETP53 | |
| SCHEMBL6703494 | 0.78 | DRD4 (0.35) | SMN1; SMN2RGS4RGS8METSSTR5 | |
| SCHEMBL6703987 | 0.77 | CLPP (0.37) | TP53ALDH1A1 | |
| SCHEMBL6704154 | 0.75 | MMP13 (0.39) | MAPTLMNASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL6697999 | 0.71 | L3MBTL1 (0.32) | MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6814225 | 0.69 | P2RX7 (0.35) | MAPTLMNAACHERGS4RGS8 | |
| SCHEMBL6697077 | 0.68 | CLPP (0.31) | MAPT | |
| SCHEMBL6697086 | 0.68 | KDM4E (0.30) | MAPT | |
| SCHEMBL6697998 | 0.68 | MMP13 (0.45) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL6818750 | 0.65 | MMP13 (0.37) | MAPTACHEMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MAPT 4548/4885LMNA 2847/4885SMN1; SMN2 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.